Biyobelirteçler koroner yavaş akım patogenezini anlamamıza yardımcı olabilir mi?
C oronary slow-flow phenomenon (CSFP) is a well-defined clinical entity but with unclear etiology. CSFP, which can be detected during coronary angiography (CAG), is defined as delayed filling of the distal parts of the coronary arteries without significant stenosis in the epicardial arteries. [1] Firstly, in 1972, Tambe et al. [2] reported CSFP as a cause of chest pain. CSFP is seen in 1-7% of patients undergoing diagnostic angiography. [3] In particular, the role of endothelial dysfunction and subclinical diffuse atherosclerosis in the developmental mechanism of CSFP has been emphasized. [4] [5] [6] Since the pathophysiologic mechanism is not clearly defined, the treatment strategy is also not clear.
Endocan, also called endothelial cell-specific protein, is a pretoglycan that is released from endothelial cells and can be measured in serum. [7] Recent studies have shown that endcan plays a key role in endothelial dysfunction, particularly as an adhesion molecule in inflammation-related processes. [8, 9] Omentin-I is a 34 kDa soluble lectin released from stromal vascular cells of visceral fat tissue. [10] Circulating omentin-I levels were found to be negatively correlated with body mass index (BMI), leptin levels, insulin resistance, waist circumference, homeostasis, but positively correlated with high-density lipoprotein levels. [11] As observed in various clinical studies omentin-I has a metabolismprotective effect which is thought to be caused by its antiinflammatory property, and it demonstrates a negative correlation with coronary artery disease. [12, 13] In our study, we investigated the relationship between endothelial and atherosclerosis-related omentin-I molecules associated with endothelial dysfunction and CSFP.
METHODS

Study group
In this cross -sectional study, 42 patients with stable angina pectoris who had coronary slow-flow phenomena detected as a result of noninvasive tests were included in the study. Forty-three patients with similar ages and totally normal coronary arteries (NCAs) were included in the study as the control group. cases with acute coronary syndrome, history of known coronary artery disease and coronary bypass surgery, systolic heart failure (left ventricular ejection fraction <40%), chronic or active infection, chronic kidney and liver, dysfunction, patients with a history of malignancy were excluded from the study. The local ethics committee of our hospital approved our study protocol (Date: 09.01.2018, no: 931) and a written informed consent form was received from participants before they were included in the study.
Individuals who had blood pressures ≥140/90 mm Hg in repeated measurements, and antihypertensive drug users were considered as hypertensive patients. Patients with plasma glucose level ≥126 mg/dL in repeated measurements or who were on antidiabetic medications were considered as diabetic patients.. Body mass index was calculated by dividing body weight (kg) by square of height (cm) (kg/m 2 ).
Coronary angiography and calculation of TIMI-TFC
All angiographies were performed through femoral artery using the standard Jutkins technique. Images were recorded at a rate of 30 frames per second. The presence of CSFP was determined by thrombolysis in myocardial infarction (TIMI) frame count (TFC) method. [14] TFC was calculated separately for each coronary artery by two cardiologists who did not know the patient's clinic. The frame in which the opaque material delivered forward filled up 70% of the coronary artery diameter was noted as the first frame. Apical portion of the left anterior descending artery (LAD), distal bifurcation of the farthest enlarged lateral branch of the circumflex (Cx) artery, and filling of the first branch of the posterior lateral branch of the right coronary artery (RCA) were accepted as the last frame. Since the LAD was longer than the other arteries, the corrected TFC was calculated by dividing the TFC value by 1.7 
Collection of data
Venous blood samples were taken 1 hour after the procedure from both patients with coronary slow flow detected during angiography and patients with normal coronary artery to be included in the control group. Samples were centrifuged at 3000 g immediately after collection and stored at -80 ° C until analysis. Serum cholesterol, glucose, and creatinine levels were measured by standard techniques on an automated biochemistry analyzer (Hitachi 7600 Automatic Biochemical Analyzer, Hitachi Co., Japan). Blood samples for complete blood count were measured on an automated hematology analyzer Sysmex XT-1800i (Roche Diagnostic Corporation, Indianapolis, IN, USA). Serum endocan levels were measured by enzyme-linked immunosorbent assay (ELISA) (Endocan ELISA kit, Eastbiopharm Co., China). Serum omentin-1 levels were also determined by the ELISA kit with high specificity and sensitivity (Sunred Biotechnology Co., Shanghai, China).
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate the distribution model. Normally distributed numerical variables were presented as mean ± standard deviation, and abnormally distributed ones as medians and interquartile range (IQR). The significance of the difference between the groups in terms of mean values was evaluated by Student's t-test and Mann-Whitney U test for the continuous numerical variables with nonnormal distribution. Chi-square test was used to compare categorical variables. Regarding categorical data, if the expected frequency in any of the cells remained between 5-25 in the 2x2 cross-tables, continuity correction chi-square test was used. Spearman rank test was used to determine whether there was a correlation between mean TFC and serum endocan and omentin-I levels. Receiver operating characteristic (ROC) curve analysis was used to estimate the sensitivity, specificity, and cut-off of serum endocan and omentin-I levels in the prediction of CSFP. Logistic regression analysis was used to evaluate predictors of slow coronary flow. As a result of univariate statistical analyzes, variables with p<0.25 was included in the multivariate logistic regression model. The statistical significant was accepted as p<0.05 within 95% confidence interval.
SPSS 22.0 Statistical Package Program for Windows (SPSS Inc., Chicago, Illinois) was used in all statistical analyzes.
RESULTS
A total of 85 patients were included in the study (CSFP group n=42 and NCA group n=43). The median age of the CSFP group of patients was 60 (62-55) years and 76% of this group consisted of male patients, while the median age of the NCA group was 57 (62-51.5) years and 19% of the control subjects comprised of male individuals. Clinical and laboratory features are presented in Table 1 and angiographic features in Table  2 . Male gender, BMI and hypertension were significantly higher in the CSFP group. Red cell distribution width (RDW) and platelet counst were significantly lower in the CSFP group compared to the NCA group (Table 1 ). In the CSFP group, serum omentin-I levels were significantly lower and serum endocan levels were significantly higher relative to NCA group (Table 1 ). All TFCs were significantly higher in the CSFP group (Table 2 ).
In the ROC curve analysis, the area under the curve (AUC) for the endocan was 0.760, and AUC for the omentin-I was 0.630 (95% CI: 0.65-0.86, p<0.001 and 95% CI: 0.51-0.75 p=0.049, respectively Fig. 1) . The values determined by the ROC curve analysis were verified by kappa test and the best cut-off values were determined. With a cut-off value of 2.45 ng/ mL, 66% sensitivity and 70% specificity predicted the presence of CSFP. The cut-off value for omentin-I was 4.63 ng/mL with 66% sensitivity and 61% specificity. For predicting coronary slow-flow phenomenon, the positive, and negative predictive values of omentin-I, were 0.61 ng/mL and 0.75 ng/mL, respectively. For endocan, the positive, and negative predictive values were 0.82 ng/mL and 0.71 ng/mL, respectively.
Spearman correlation analysis showed a statistically significant positive correlation between serum endocan levels and mean TFC and a statistically significant negative correlation between serum omentin-I levels and mean TFC values (r=0.44, p<0.001 and r=respectively). -0.22, p=0.049; Fig. 2 ). Male gender, BMI, hypertension, serum omentin-I and endocan levels with estimated p value of <0.25 in univariate analysis were included in multivariate analysis, the factors discriminating between both groups most accurately were identified using "Backward LR" method. In multivariate regression analysis, low serum omentin-I levels (OR: 3.6, 95% CI: 1.057-12.893, p=0.041, cutoff value: 4.63 ng/mL), high serum endocan levels (OR: 6.8, 95% CI): 1.849-2.439, p=0.003, cut-off value: 2.45 ng/mL), male sex and high BMI (OR: 5.0, 95% CI: 1.338-19.230, p=0.017 and OR: 1.3 95% CI: 1.075-1.655, p=0.009, respectively) were detected as independent predictors in CSFP (Table 3) .
DISCUSSION
In our study, omentin-I associated with diffuse atherosclerosis and endocan levels associated with endothelial dysfunction were investigated in patients with coronary slow-flow phenomenon. tion, differentiation, migration and recruitment of cell types. [7] Endocan released from a stimulated endothelial cell creates an environment in which the leukocytes adhere to the endothelial cell which is thought to initiate the process of endothelial dysfunction. [15] In a recent study, similar to the results of our study, TFC was found to be an independent predictor of CSFP together with high endocan levels. [16] In addition, it has been shown that mean TFC increases significantly as endocan levels increase. This result shows that endocan levels, which are independent predictors in CSFP, also determine the severity of CSFP.
Omentin-I is a glucoprotein of the adiponectin family released from visceral adipose tissue.In addiIt was observed that mean TFC increased significantly as endothelial levels increased with decreasing omentin-I levels in patients with CSFP.
In addition, low omentin-I and high endocan levels were found to be independent risk factors for CSFP. Higher number of male individuals and increased BMI in addition to omentin-I and endocan were also detected as independent risk factors for CSFP.
Endocan is a proteoglycan, also known as endothelial cell-specific molecule released from endothelial cells. Similar to other proteoglycans, it can bind to a variety of bioactive molecules associated with cellular signaling and adhesion and regulates the prolifera- thickness which predicts premature coronary artery disease increases in patients with CSFP. [22] Beltrame et al. [23] performed separate measurements during repeated coronary angiographies, after coronary sinus cannulation and rapid atrial stimulation, cold stimulation, and acetyl choline infusion to demonstrate endothelial dysfunction in CSFP patients, and found that vasomotor tone at rest was significantly higher. Mibefradil, a calcium channel blocker, has been shown to reduce anginal symptoms in patients with CSFP and average TFC values which was considered to be the result of the positive effects of mibefradil against endothelial dysfunction. [24] In the study of Sezgin et al., [6] flow-mediated dilatation of the brachial artery, which is an indicator of endothelial dysfunction, was found to be significantly less frequent among CSF patients.
Although these studies have helped us to understand the pathogenesis of CSF, they did not provide a precise result. There is no consensus as to which mechanism plays a more important role or to what extent these mechanisms are interrelated. Comparison between diffuse atherosclerosis and endothelial dysfunction is difficult as it involves interventional procedures. Therefore, studies with biomarkers may help us to give an idea about the pathophysiological mechanism. In our study, it was concluded that endocan and omentin-I molecules, which are associated with endothelial dysfunction and subclinical atherosclerosis, are independent predictors of CSFP. This result suggests that both mechanisms play a role in the pathophysiology of these patients.
The most important limitation of our study was the relatively small number of patients. Another limitation was that we didn't examine the markers of inflammation such as hsCRP and IL-6 which increase also in atherosclerosis. In addition subclinical atherosclerosis was not evaluated by invasive (IVUS, etc.) or noninvasive methods (carotid intima media measurement, etc.).
In conclusion, endocan and omentin-I molecules are two molecules that can be used as independent predictors in the CSF phenomenon. Decrease in serum omentin-I, but increase in endocan levels are directly proportional to the severity of coronary slow flow. In addition, studies with coronary slow-flow phenomenon and different biomarkers can guide the understanding of pathogenesis of CSFP. tion to visceral adipose tissue, it is also synthetized -though at a lesser quantity -from Paneth cells, endothelial cells and visceral fat stromal-vascular cells. [10] Omentin-I is a protective adiponectin with anti-inflammatory effect in different atherosclerotic processes. In addition to its prevalence in peripheral artery, and coronary artery disease, lower omentin-I levels were observed in inflammatory bone diseases and end-stage renal disease patients undergoing hemodialysis. [12, [17] [18] [19] In the study of Ucgun et al. -though not statistically significant-lower omentin-1 levels were detected in patients with CSFP, however visfatin-an adiponectin-was found to be an independent predictor Forty-five patients with CSFP and 55 participants with NCA were included in this study,and the relationship between CSFP and omentin and visfatin molecules was investigated. The relationship between CSFP and omentin was evaluated only in univariate regression analysis and was not included in multivariate regression analysis.
In our study, univariate regression analysis with omentin-I, a level of statistical significance could not be reached, but in the multivariate regression analysis, serum omentin-I levels were found to be independent predictors in CSF patients. In our study, the relationship between omentin-I and coronary slow flow was evaluated by ROC curve analysis and Spearman correlation analysis.
ROC curve analysis also supported the results of regression analysis. In addition, Spermman correlation analysis showed that mean TFC increased significantly as the omentin-I level decreased. The protective role of omentin-I in many metabolic disorders has been also observed in CSFP. Low levels of omentin-I may be related to the inflammatory process in CSFP and also diffuse atherosclerosis that does not lead to narrowing of the coronary arteries.
Although many mechanisms related to the pathogenesis of CSF have been emphasized, most studies have been conducted on endothelial dysfunction and subclinical diffuse atherosclerosis. Cin et al. [21] examined patients with CSFP using intravascular ultrasound (IVUS) and fractional flow reserve (FFR).
Longitudinally dilated calcification in the coronary arteries leading to ischemia without narrowing the lumen was found in patients with CSFP. As demonstrated in another study, carotid intima-media
